Ocaratuzumab (AME 133v),一种 Fc 工程抗体,是人源化的 IgG1 抗CD20单克隆抗体,Kd值为 ~100 pM。Ocaratuzumab 表现出更有效的抗体依赖性细胞介导的细胞毒性 (ADCC)。
生物活性 | Ocaratuzumab (AME 133v) is an Fc-engineered humanizedIgG1anti-CD20monoclonal antibody, with aKdof ~100 pM. Ocaratuzumab exhibits more effective antibody-dependent cell-mediated cytotoxicity (ADCC)[1][2]. |
IC50& Target | |
体外研究 (In Vitro) | AME-133v (0.027-20 μg/mL) 浓度依赖性地抑制了 SKW6.4 细胞中生物素化利妥昔单抗与 CD20 的结合[1]。
|
CAS 号 | |
储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |